Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIJEX vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Management of secondary hyperparathyroidism in patients with chronic kidney disease stage 3, 4, and 5 on dialysis,Hypocalcemia in patients with hypoparathyroidism,Hypocalcemia in renal osteodystrophy,Off-label: treatment of hypocalcemia due to pseudohypoparathyroidism or vitamin D-dependent rickets
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life ranges from 5 to 10 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 20 hours or more.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Primarily hepatic via 24-hydroxylation; also undergoes further oxidation and conjugation. Not significantly metabolized by CYP450 enzymes.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Primarily hepatic (biliary-fecal) elimination; approximately 2-4% excreted unchanged in urine. Small amount undergoes enterohepatic recirculation.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Approximately 99.9% bound to vitamin D-binding protein (DBP) and albumin.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
Volume of distribution (Vd) is approximately 0.25 L/kg (range 0.2-0.3 L/kg). This low Vd indicates distribution mainly to extracellular fluid and tissues.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Oral bioavailability is approximately 60-70% when administered as the injectable formulation orally; however, for IV administration, bioavailability is 100%.
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
For GFR < 30 m L/min: reduce initial dose to 0.25 mcg oral or 0.5 mcg IV three times weekly. No adjustment for GFR > 30 m L/min.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
No specific recommendations for Child-Pugh classes; caution in severe hepatic impairment due to risk of accumulation.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
Intravenous: 0.01-0.05 mcg/kg three times weekly; titrate based on calcium and PTH levels. Oral: 0.015-0.025 mcg/kg once daily.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Start at low end of dosing range (0.25 mcg oral or 0.25-0.5 mcg IV three times weekly); monitor calcium and phosphate closely due to increased sensitivity.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
None
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
Hypercalcemia, hypercalciuria, hyperphosphatemia; aluminum hydroxide use may increase aluminum absorption; avoid vitamin D supplementation; monitor serum calcium and phosphate levels regularly; caution in patients with coronary artery disease (calcium load).
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Hypercalcemia, vitamin D toxicity, known hypersensitivity to calcitriol or any component of the formulation.
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Avoid excessive dietary calcium (dairy products, fortified foods) during treatment. Do not take calcium-containing antacids or supplements. Maintain adequate fluid intake to prevent hypercalcemia.
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
Calcitriol (CALCIJEX) is a Vitamin D analog. Based on animal studies, there is evidence of teratogenicity at high doses (skeletal abnormalities, reduced fetal weight). Human data are limited. Pregnancy Category C. First trimester: Theoretical risk of teratogenicity if hypercalcemia occurs; avoid excessive doses. Second and third trimesters: Risk of fetal hypercalcemia and suppression of parathyroid function if maternal hypercalcemia develops; use only if clearly needed and monitor maternal calcium levels.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Calcitriol is excreted into human breast milk but in low amounts. No adverse effects reported in nursing infants. The M/P ratio is not established. Caution is advised due to risk of hypercalcemia in the infant; monitor infant serum calcium if maternal use is necessary.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
Dosing adjustments may be required due to altered calcium metabolism in pregnancy. Increase in glomerular filtration rate (GFR) and expanded plasma volume may increase clearance, potentially requiring higher doses. However, maintain normocalcemia; monitor serum calcium and adjust dose accordingly. Starting dose typically unchanged but may need titration based on calcium levels.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
Monitor serum calcium and phosphate levels closely; hypercalcemia risk is highest with concurrent thiazide use or high calcium intake. Adjust dose based on PTH levels in CKD patients. Use with caution in digitalis-treated patients due to additive positive inotropic effect.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Take this medication exactly as prescribed; do not change dose or frequency without consulting your doctor.,Alert your doctor if you experience symptoms of high calcium: nausea, vomiting, constipation, muscle weakness, or confusion.,Avoid excessive intake of calcium-rich foods, supplements, or antacids during treatment.,You may need regular blood tests to monitor calcium, phosphate, and parathyroid hormone levels.,Inform all healthcare providers that you are taking Calcijex.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
No interactions on record
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIJEX vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
CALCIJEX is a Vitamin D Analog that works by Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIJEX and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIJEX is: Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.. The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIJEX and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIJEX is classified as Category C. Calcitriol (CALCIJEX) is a Vitamin D analog. Based on animal studies, there is evidence of teratogenicity at high doses (skeletal abnormalities, reduced fetal weight). Human data a. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.